title: PD-1 Antibody-induced Guillain-Barré Syndrome in a Patient with Metastatic Melanoma.
authors.affiliation: Department of Dermatology and National Center for Tumor Diseases, University of Heidelberg, Im Neuenheimer Feld 440, DE-69120 Heidelberg, Germany. roland.schneiderbauer@med.uni-heidelberg.de.
authors.forename: Roland
authors.initials: R
authors.lastname: Schneiderbauer
authors.forename: Malessa
authors.initials: M
authors.lastname: Schneiderbauer
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Wick
authors.forename: Alexander H
authors.initials: AH
authors.lastname: Enk
authors.forename: Holger A
authors.initials: HA
authors.lastname: Haenssle
authors.forename: Jessica C
authors.initials: JC
authors.lastname: Hassel
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects; D020275:Guillain-Barre Syndrome / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008875:Middle Aged; D009460:Neurologic Examination; D000077594:Nivolumab; D011237:Predictive Value of Tests; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors* / Q000276:immunology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab